Damora Therapeutics starts Phase 1/1b CLARITY-101 trial of DMR-001 in mutant CALR-driven ET, myelofibrosis
DMRA•Phase 1/1b trial launched in mutant CALR-driven disease
Damora Therapeutics launched the Phase 1/1b CLARITY-101 trial of DMR-001 in mutant CALR-driven essential thrombocythemia and myelofibrosis.
Initial trial results have not been presented; first data are expected from mid-2027.
The study aims to assess safety, tolerability, and early signs of benefit for a once-monthly subcutaneous antibody designed to block the disease driver.
The development strategy targets patients who failed prior standard therapies, with a later expansion planned for earlier use and combination settings.
